BioCryst Pharma (BCRX) Prices 37.93M Share Common Offering at $1.45/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Pre-Open Movers 11/13: (CDLX) (CHK) (TWOU) Higher; (APDN) (SSTI) (SDC) Lower (more...)
November 13, 2019 9:25 AM ESTToday's Pre-Open Movers
Applied DNA Sciences, Inc. (NASDAQ: APDN) 75.6% LOWER; announced the pricing of an underwritten public offering of 2,285,000 shares of its common stock and warrants to purchase up to an aggregate of 2,285,000 shares of common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined effective price to the public of $5.25 per share and accompanying warrant. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $12.0 million, not including any... More
After-Hours Movers 11/12: (CLDX) (TWOU) (DDOG) Higher; (SSTI) (SDC) (CSIQ) Lower (more...)
November 12, 2019 5:40 PM ESTToday's After-Hours Movers
Cardlytics (NASDAQ: CDLX) 22.6% HIGHER; reported Q3 EPS of $0.03, $0.18 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $56.4 million versus the consensus estimate of $50.06 million. Cardlytics sees Q4 2019 revenue of $55-59 million, versus the consensus of $55.74 million. Cardlytics sees FY2019 revenue of $195-200 million, versus the consensus of $190.49 million.
2u (NASDAQ: TWOU) 14.4% HIGHER; reported Q3 EPS of ($0.41), $0.09 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $153.8 million versus the consensus... More
BioCryst Pharma (BCRX) Commences $55M Public Offering of Common Stock
November 12, 2019 4:06 PM ESTBioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it is offering to sell $55 million of its common stock in an underwritten public offering. As part of this offering, BioCryst intends to grant the underwriters a 30-day option to purchase up to an additional $8.25... More



